The global breast cancer therapeutics market is projected to grow from USD 39.46 billion in 2025 to USD 95.14 billion by 2035, with a CAGR of 9.20%. Growth is driven by increased adoption of targeted therapies, CDK4/6 inhibitors, immunotherapy, and antibody-drug conjugates. North America leads with 38.61% market share, while Asia Pacific shows the fastest growth. Targeted therapy dominates with 64.85% share, while immunotherapy is the fastest-growing segment at 14.25% CAGR.

Eli Lilly's oncology revenues grew 11% to $4.84 billion in H1 2026, with newer drugs like Jaypirca (up 66%) and Inluriyo driving diversification beyond its flagship Verzenio. The company strengthened its blood-cancer pipeline through acquisitions of Ajax Therapeutics and Kelonia. However, Lilly faces intense competition from AstraZeneca, Merck, and Pfizer in the oncology space. The stock trades at a premium valuation (28.03x forward P/E) but holds a Zacks Rank #3 (Hold) rating.

The global mRNA vaccines market for non-COVID applications is projected to grow at a 109% compound annual growth rate from $9 million in 2026 to $7.04 billion by 2035. Market expansion is driven by advancing clinical pipelines, diversification into influenza, RSV, oncology and next-generation RNA technologies, with over 100 mRNA-based cancer candidates under investigation. Influenza is expected to become the leading indication by 2035, while North America remains the largest regional market.

Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.

Pfizer faces significant patent expirations for major drugs (Ibrance, Xtandi, and Eliquis) between 2027-2028, which is pressuring its stock valuation and causing investor concern. However, the company is expected to recover by 2030 through new drug development and acquisitions, with management predicting high-single-digit revenue growth post-2028. While the company maintains an attractive 6.4% dividend yield, ongoing patent cliff risks remain a structural challenge for the business.

Protalix reported Q2 2026 revenues of $19.9 million, up from $15.7 million year-over-year, driven by Elfabrio sales through its Chiesi partnership. The company posted net income of $3.8 million ($0.05 per share) and H1 net income of $22.1 million. Full-year 2026 revenue guidance remains $78-83 million. The company maintains a strong cash position of $40.7 million with zero debt and expects PRX-115 Phase 2 RELEASE study top-line results in H2 2027.

AbbVie and Bristol-Myers Squibb are compared as dividend-paying pharmaceutical investments. AbbVie shows stronger revenue growth (8.6% YoY) driven by Skyrizi and Rinvoq, while Bristol-Myers Squibb faces patent cliff headwinds despite trading at a significant valuation discount. The article recommends AbbVie for long-term investors due to its focused operations, accelerating neuroscience portfolio, and attractive dividend, despite Bristol-Myers Squibb's recovery potential.

Eli Lilly's weight-loss pill Foundayo received U.K. approval, marking Europe's first GLP-1 oral medication authorization. The drug offers advantages over competitor Novo Nordisk's Wegovy with no food restrictions. The global obesity drug market is projected to grow from $66 billion in 2025 to $92-200 billion by 2027, presenting significant growth opportunities for multiple manufacturers.

The article compares AbbVie and CVS Health as healthcare investment options in 2026. AbbVie, a biopharmaceutical company with a $438B market cap, is recommended as the better choice due to its focused growth trajectory, strong drug pipeline (Skyrizi and Rinvoq), and attractive dividend yield. CVS Health, a diversified healthcare provider with a $122B market cap managing 37 million medical members, is acknowledged as a turnaround story showing stabilization but is considered less compelling than AbbVie's growth prospects.

Pfizer is developing berobenatide, a monthly injectable weight-loss drug that could compete with market leaders Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Phase 2b data shows 16% weight loss in 32 weeks with no plateau, positioning it as potentially competitive despite lower efficacy than rivals. The anti-obesity market is projected to reach $190 billion by 2035, offering significant opportunity, though Pfizer faces risks from patent cliffs, increased competition from companies like Amgen, and regulatory hurdles.

ResearchAndMarkets.com released a comprehensive report analyzing 1,350+ precision medicine collaboration and licensing deals from 2019-2026. The report provides detailed benchmarking data on deal structures, financial terms, and contract provisions to support business development and strategy decisions in the precision medicine sector.

The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, growing at a 7% CAGR. Market expansion is driven by rising public health awareness, an aging population, government immunization programs, and increased R&D investment. Quadrivalent and inactivated vaccines lead the market, while cell-based technologies and pediatric segments show fastest growth. Key players include GlaxoSmithKline, Pfizer, Sanofi, Moderna, and others.